Biotech Startups

REOME sells high-performance skincare products, including serums, creams, and eye treatments powered by biotechnology and bio-active ingredients such as DHK-3. It offers a direct-to-consumer collection of clinically-focused products aimed at hydrating, smoothing, and firming skin.

1 investor

REPROCELL provides research services and products for stem cell and drug discovery scientists, including iPSC tools, gene editing, GMP cell manufacturing, human tissue testing, and biospecimen processing. It serves cell therapy developers, stem cell researchers, diagnostic developers, and preclinical and clinical drug developers across the research-to-clinic pipeline.

1 investor

Reprogram Biosciences develops an in vivo immunotherapy that uses a therapeutic gene cocktail delivered via lipid nanoparticles to reprogram solid-tumor cancer cells into immune-like cells. The company operates in the biotech and cancer therapeutics field, applying gene reprogramming and AI-driven bioinformatics to develop cell therapies for solid tumors.

1 investor

REPROSENT captures patient treatment experience data to support dose, safety, and development decisions in oncology and advanced cancer therapies. The platform operates as a lightweight, non-interventional overlay on existing clinical trials and care programs, converting patient symptoms into structured, computable signal for development and clinical teams.

1 investor

resbiotic develops physician-formulated prebiotic, probiotic, and postbiotic supplements alongside microbiome testing to address gut health and chronic conditions. The consumer wellness brand bases its products on clinical trials and scientific research, offering personalized restoration recommendations.

1 investor

Everlife-Research Instruments supplies research tools, laboratory equipment, and analytical solutions to the scientific and clinical community in Asia. The company provides a full range of services from product distribution to technical support, regulatory guidance, and laboratory design.

1 investor

ResearchSat is a CRO/CDMO providing microgravity research services for biopharma and life-science teams, running staged studies from ground screening to orbital experiments to generate CMC-relevant data for biologics, formulations, and translational R&D. It designs experiments, builds payloads, manages missions, and delivers decision-grade datasets with regulatory-aware documentation for biotech companies, government agencies, and research institutions.

1 investor

Resilient Medical Corp designs an implantable device, Bravo, placed during breast cancer lumpectomy surgery to support tissue healing, avoid follow-up cosmetic reconstruction, and act as a radiocontrast marker for post-operative therapy. The company targets breast cancer surgical patients and clinicians in the medical device industry.

1 investor

Resistomap provides environmental surveillance and monitoring solutions for antibiotic resistance using microbiology and data science expertise. The company serves global communities, organizations, and projects focused on tracking antibiotic resistance across environmental, animal, and human health domains.

1 investor

Resolian is a Contract Research Organization (CRO) that provides bioanalytical, biomarker, and analytical sciences services to support drug development for pharma and biotech companies. The company specializes in GxP and non-regulated bioanalysis, drug metabolism and pharmacokinetic services, and GMP CMC analytical and materials science across all therapeutic modalities.

1 investor

Resolute Science appears to be a clinical-stage therapeutics company focused on oncology and cancer treatment development. The team includes medical oncologists, regulatory experts, and scientific advisors with experience in phase 1-3 clinical trials and precision medicine.

1 investor

Resolution develops a macrophage cell therapy to treat end-stage liver disease, aiming to reduce the need for liver transplantation and improve patient outcomes. The company focuses on regenerative medicine for inflammatory and fibrotic diseases.

1 investor

Resolve Nanotherapeutics is developing RNA drugs delivered via lipid nanoparticles that amplify the body's toxin-clearance pathway to treat severe acute bacterial infections and their chronic complications. Its host-focused therapy targets the immune system rather than the bacteria, aiming to work against antibiotic-resistant infections in critical care settings.

1 investor

Response Bio develops the RAMP platform, which delivers acute care diagnostic testing with lab-quality results within minutes to support rapid clinical decision-making in healthcare settings. The company serves medical teams and partners seeking to reduce diagnostic turnaround time and total cost of care.

1 investor

Response Pharmaceuticals is a clinical-stage drug developer working on RDX-002, a small-molecule iMTP inhibitor for weight management and metabolic health, including post-GLP-1 receptor agonist weight management and antipsychotic-induced weight gain. The company is advancing the candidate through Phase 2 clinical trials.

1 investor

ResQ Pharma is a pharmaceutical company developing LipidRescue (LRT), an investigational lipid-based drug therapy that is pending FDA approval. The company works on biologics development, regulatory affairs, and clinical research for its drug candidate.

1 investor

ReSync Bio provided drug discovery teams with no-code access to AI tools for molecular design and analysis, removing the need to build their own infrastructure. The company has been acquired by Benchling and is sunsetting its platform.

1 investor

Retension Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for hypertension and cardiovascular disease. The company's lead compound, RTN-001, is a tissue-targeted PDE5 inhibitor designed to treat resistant hypertension through a differentiated mechanism targeting the central pulmonary vasculature.

1 investor

Reticular offers an at-home saliva (cheek swab) genetic screening service that tests 750+ reproductive genes in one or both partners, paired with licensed genetic counseling, to provide context on fertility, early embryo development, and pregnancy loss. It serves people planning a pregnancy, those with unexplained infertility or recurrent pregnancy loss, and also offers embryo reports for users with existing embryo sequencing data.

1 investor

RetMap develops next-generation electroretinography sensors and diagnostic medical devices for screening, diagnosis, and treatment of neurodegenerative eye conditions. The company serves ophthalmologists and clinicians seeking to detect and manage retinal diseases and prevent vision loss.

1 investor

Revadix develops first-in-class small molecule therapies targeting the EPAC1 signalling pathway to treat atrial fibrillation, addressing the underlying disease mechanism rather than symptoms. Its lead asset AM-001 is entering IND-enabling studies while a second EPAC1-targeting program is in lead optimization, aimed at cardiac arrhythmia patients.

1 investor

Revagenix is a precision-therapeutics company that develops drugs for serious chronic diseases, starting from the underlying biology and unmet clinical needs. Its lead program, Rev-56, is an inhaled therapy with a novel mechanism of action designed for non-CF bronchiectasis (NCFB).

1 investor

REVA Medical develops bioresorbable polymers for medical implants, with a focus on vascular applications. The company creates drug-eluting bioresorbable scaffolds for treating coronary artery disease, positioned as an alternative to permanent metallic stents.

1 investor

Revascular Bio develops cell therapy treatments using vascular endothelial stem cells to address diseases caused by vascular dysfunction, including chronic wounds, severe limb ischemia, and genetic blood disorders. The company targets intractable diseases with angiogenic therapy, angiocrine therapy, and protein production platforms.

1 investor